Affiner les résultats

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

van den Bent, M. J. ; Grisold, W. ; Frappaz, D. ; Stupp, R. ; Desir, J. P. ; Lesimple, T. ; Dittrich, C. ; de Jonge, M. J. A. ; Brandes, A. ; Frenay, M. ; Carpentier, A. F. ; Chollet, P. ; Oliveira, J. ; Baron, B. ; Lacombe, D. ; Schuessler, M. ; Fumoleau, P.

In: Annals of Oncology, 2003, vol. 14, no. 12, p. 1732-1734